CHM has a big competitor Treovir,LLC. They attended the recent AACR weekend. Here is an excerpt from an email that I received.
“Thank you for your interest. We are currently a privately held company that has acquired all of the materials and world-wide rights for G207 from Aettis. We have Fast Track Designation for G207 and Orphan Drug Designation for glioma, ependymoma, medulloblastoma and primitive neuroectodermal tumors for G207. I will send your email to our CEO, Michael Christini, in case he can answer any of your questions. Thanks for your interest in Treovir.
”
Ann: Successful Completion of Dosing in First Patient Cohort, page-35
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $11.76K | 2.928M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 4817793 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 18563373 | 21 |
View Market Depth
| Last trade - 14.13pm 26/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |